Veronika Oudova
Veronika is a co-founder and Chief Executive Officer of S-Biomedic.
Veronika completed a master study in International Trade in Prague and a master in International Management within the program CEMS located in Prague, Vienna and Rotterdam. After her studies she has worked as project manager and marketing consultant at Cord Blood Bank Czech Republic. There she also co-founded a spin-off company StemCellPro.
Before joining the project S-Biomedic Veronika has worked as account manager, business analyst and quality manager in the market research industry.
Trevor Steyn
Trevor Steyn is the CEO and founder of Esse Skincare. As an organic chemist his research has taken a broader approach to optimising skin health in the long term. Esse launched its first live probiotic product in February 2015 and has subsequently pioneered several new technologies in modulating the skin microbiome.
Thomas Hitchcock
Thomas Hitchcock is the founder and CEO of Xycrobe Therapeutics. An entrepreneur in the biotech space, Thomas has been instrumental in bringing several medical technologies successfully to the dermatological and aesthetics markets. Thomas holds a doctorate in molecular genetics from Clemson University where he did his research on DNA damage and repair. He has completed postdoctoral training at both Duke University in the Biomedical Engineering Department and Yale University in the Program in Vascular Biology and Therapeutics where he was involved in ground-breaking research and development of in vitro engineered human cardiovascular and pulmonary tissues. He has also performed research at Weill Cornell Medical College in the Department of Oncology and Hematology where he studied multiple myeloma genetics. Prior to Xycrobe, he was the Director of Medical Affairs for Ulthera, Inc., and part of the team that brought their platform technology to acquisition in July 2014 by Merz pharmaceuticals. Thomas also currently travels the country lecturing to medical professionals about skincare and aesthetics in dermatology.
Riëtte van Laack
Riëtte van Laack, Ph.D., provides regulatory counsel on OTC products, including foods and dietary supplements, OTC drugs, cosmetics, and animal feed and drugs on a range of FDA, USDA, FTC, and CPSC issues.
Ms. van Laack has substantial experience with food and dietary supplement issues, labeling and advertising. She counsels clients regarding GMP and HACCP compliance issues, Reportable Food Registry issues, and responses to warning letters. Ms. van Laack advises clients on regulatory strategy, including requirements pertaining to self-determinations of GRAS status and determinations of new dietary ingredient status. Ms. van Laack also has substantial experience with regulation regarding labeling and advertising of over-the-counter (OTC) drugs and cosmetics. Ms. van Laack’s practice includes USDA regulatory issues ranging from requirements for import of animal products (APHIS), use of ingredients in meat, poultry, and egg products (FSIS), and organic labeling requirements (AMS). Ms. van Laack conducts due diligence evaluations of FDA- and USDA-regulated companies. She additionally assists clients with compliance and liability issues related to products regulated both by the CPSC and FDA.
Ms. van Laack has advanced degrees in Nutrition and Meat Science, and more than 15 years experience in food research. Ms. van Laack was a professor at the Department of Food Science and Technology at the University of Tennessee. While in law school, Ms. van Laack was an Articles Editor of theTennessee Law Review.
Raymon uit de Bulten
Julia Straus
Julia Oh
Dr. Oh's main research interests focus on the human microbiome—the diverse bacteria, fungi, and viruses that inhabit our bodies—for its potential to deliver treatments for infectious and other diseases. Dr. Oh comes to the microbiome world by way of fungal chemogenomics with technologist and geneticist Dr. Ronald Davis at Stanford and comparative genomics of wild wine yeast at the FAS Center for Systems Biology at Harvard. Prior to joining the Jackson Laboratory, she was a postdoctoral fellow at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health. Dr. Oh's research, exploring the complex interactions between the host and its microbes has lead to important implications for the contribution of the microbiome to disease.